Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study

NCT00823524 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT00823524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00823524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study
Lead sponsor
Asan Medical Center
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2009
Completion date
February 28, 2013
Enrollment
47 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors, chronic myeloproliferative disorders, leukemia, lymphoma, lymphoproliferative disorder, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, unspecified adult solid tumor, protocol specific